Leveraging Precision Antigen Discovery & Novel CD3 Bispecific Design to Enable Safer B-Cell Depletion in Autoimmune Disease
- Utilizing the T-Ca platform to identify disease-driving antigens and pathogenic immune-cell populations, enabling the development of highly selective therapies that minimize off-target immune depletion and improve therapeutic precision
- Translating a CD3 bispecific platform originally developed for oncology into autoimmune disease, applying established insights into target engagement, immunecell depletion, and safety management to accelerate clinical development
- Integrating translational biology and patient-derived immune profiling to optimize target selection, improve benefit-risk profiles, and deliver more effective and durable outcomes for patients with autoimmune disease